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Background: One of the primary dose-limiting toxicities during thoracic irradiation is acute esophagitis (AE). The aim
of this study is to investigate dosimetric and clinical predictors for AE grade ≥ 2 in patients treated with accelerated
radiotherapy for locally advanced non-small cell lung cancer (NSCLC).
Patients and methods: 66 NSCLC patients were included in the present analysis: 4 stage II, 44 stage IIIA and 18 stage
IIIB. All patients received induction chemotherapy followed by dose differentiated accelerated radiotherapy (DART-bid).
Depending on size (mean of three perpendicular diameters) tumors were binned in four dose groups: <2.5 cm 73.8 Gy,
2.5–4.5 cm 79.2 Gy, 4.5–6 cm 84.6 Gy, >6 cm 90 Gy. Patients were treated in 3D target splitting technique. In order to
estimate the normal tissue complication probability (NTCP), two Lyman models and the cutoff-logistic regression model
were fitted to the data with AE ≥ grade 2 as statistical endpoint. Inter-model comparison was performed with the
corrected Akaike information criterion (AICc), which calculates the model’s quality of fit (likelihood value) in relation to
its complexity (i.e. number of variables in the model) corrected by the number of patients in the dataset. Toxicity was
documented prospectively according to RTOG.
Results: The median follow up was 686 days (range 84–2921 days), 23/66 patients (35 %) experienced AE ≥ grade 2.
The actuarial local control rates were 72.6 % and 59.4 % at 2 and 3 years, regional control was 91 % at both time
points. The Lyman-MED model (D50 = 32.8 Gy, m = 0.48) and the cutoff dose model (Dc = 38 Gy) provide the most
efficient fit to the current dataset. On multivariate analysis V38 (volume of the esophagus that receives 38 Gy or
above, 95 %-CI 28.2–57.3) was the most significant predictor of AE ≥ grade 2 (HR = 1.05, CI 1.01–1.09, p = 0.007).
Conclusion: Following high-dose accelerated radiotherapy the rate of AE ≥ grade 2 is slightly lower than reported
for concomitant radio-chemotherapy with the additional benefit of markedly increased loco-regional tumor control. In
the current patient cohort the most significant predictor of AE was found to be V38. A second clinically useful
parameter in treatment planning may be MED (mean esophageal dose).
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Concomitant radiochemotherapy (CRT) is regarded as
state-of-the-art treatment for locally advanced non-small
cell lung cancer (NSCLC) achieving a median overall
survival (OAS) of approximately 17 months in previous
reports [1–3] and 28 months in the recent RTOG 0617
study [4]. Similar OAS as in earlier publications was
achieved with continuous hyperfractionated accelerated
radiotherapy (CHART), but with increased local control
[5]. Some studies explored accelerated radiotherapy after
induction chemotherapy reporting a median OAS above
20 months [6, 7]. Additionally, loco-regional control can
be increased from about 40 % in conventional dose
escalation [8, 9] to 70 % [7], yet at the potential cost of
increased toxicity.
One of the primary dose limiting toxicities is acute
esophagitis (AE), which becomes more frequent with in-
tensified treatment regimens [10, 11], ruling out the benefit
of dose escalation by causing unplanned treatment breaks.
Consequently, the highest rates of AE are seen in concomi-
tant chemotherapy plus accelerated radiotherapy [10, 12],
with severe esophagitis rates (=grade 3) up to 45 % [1].
Several predictors of acute esophagitis (AE) are currently
discussed: accelerated radiotherapy, concomitant radio-
chemotherapy (CRT), mean esophageal dose (MED), Vx
(volume receiving at least dose x), Dmax (maximum
dose to any point of the esophagus), length of esophagus
and proportion of esophageal circumference within a
specific isodose, molecular markers [13, 14], and clinical
factors such as N-stage, pretreatment dysphagia and body
mass index [10, 11, 15–24].
The aim of the present analysis was to elucidate pre-
dictors for clinically relevant AE (grade ≥ 2) in a cohort




Between January 2004 and December 2011, 166 patients
with locally advanced NSCLC (stage II–IIIB, UICC/AJCC
7th ed., 2010) were treated with dose differentiated ac-
celerated radiotherapy, twice daily fractions of 1.8 Gy
(DART-bid). Patients were discussed in a tumor board to-
gether with pneumologists, radiologists, medical oncolo-
gists, thoracic surgeons and radiation oncologists. Until
2008, the planning CT included the volume of the tumor
and the lymph nodes but did not routinely cover the
whole lung. In this study we only analyze the 66 patients
with a total lung scan: 4 stage II, 44 stage IIIA and 18
stage IIIB. 38/66 patients were treated within an observa-
tional dose escalation study performed between 01/2004
until 12/2009), the remaining 28 were treated along the
same treatment protocol but with improved image guid-
ance in a follow up study [7, 25]. Accrual for the 2nd studyperiod terminated in December 2014, however, since
the 28 patients from this second cohort had a sufficiently
long follow up (mean 637 days), they were included in the
present toxicity analysis. Overall, the median age was
65 years (range 44–83 years), the median Karnofsky Per-
formance Score (KPS) was 70 (range 50–90). All studies
were carried out with the approval of the responsible eth-
ics committee, in accordance with national law and the
Helsinki Declaration of 1975 (in its current, revised form).
Informed consent was obtained from all patients.
Radio-chemotherapy
Patients were irradiated with accelerated radiotherapy
(1.8 Gy twice daily) delivered with 15-MV photon beams
in 3D-target splitting technique [26]. Depending on tumor
size (= mean of three perpendicular diameters) patients
were allocated to four prescribed-dose groups: <2.5 cm
73.8 Gy, 2.5–4.5 cm 79.2 Gy, 4.5–6 cm 84.6 Gy, >6 cm
90 Gy. For treatment planning, patients were immobilized
in a vacuum cradle in supine position. “Slow CTs” (4 s/slice,
thickness 7 mm) were acquired. Due to the prolonged
acquisition time the GTV appears enlarged on the CT
scan, which means that it is actually a “CTV”. A margin
of 7 mm was added to the GTV and positive lymph
nodes to generate the PTV as described in a previous
report [27]. In the diagnostic work up, a PET-CT was
obligatory. Delineation of the tumor PTV was done on
the post-chemotherapeutic planning CT in the lung win-
dow, the chest window was used for the lymph nodes. For
treatment related parameters see Table 1. In the first
cohort, image guidance was performed with two orthogonal
kV images before each fraction, matching central anatom-
ical structures (esophagus, trachea, main stem bronchi). For
the second investigational period (starting in 2010), cone-
beam-CT based tumor matching was performed (with or
without marker fiducials). The following dose constraints
were applied: V20-single-lung <50 %, V25-total-lung <30 %,
Dmax for spinal cord 45 Gy, Dmax for esophagus 80 Gy.
Chemotherapy was administered in a sequential mode.
All patients received two cycles of platinum based induc-
tion chemotherapy before radiotherapy, either with
Gemcitabine or Pemetrexed. Antimycotic prophylaxis
(Amphotericine B lozengers, 4 times daily) was admin-
istered during radiotherapy.
Assessment of esophagitis
Patients were seen weekly during radiotherapy, 6 weeks
after completion of radiotherapy, then quarterly for the
first year, every four months during the second and third
year, and bi-annually thereafter. AE was documented pro-
spectively, according to RTOG, mild (grade 1), moderate
(grade 2), severe (grade 3), life threatening (grade 4), and
lethal (grade 5). A patient was scored as having acute
esophagitis if the symptoms arose during treatment or
Table 1 Patient and tumor characteristics
Patient and treatment characteristics p-value
Age Median 65 0,36
Range 44–83
KPS Median 70 0,1
Range 50–90
Sex Male 45 0,13
Female 21
Weight loss > 5 % None 49 0,7
Yes 17








UICC II: 4 x
IIIA: 44
IIIB: 18
Tumor location right lung 36 0,8
left lung 30





Histology SCC 39 0,26
AC 21
NOS 6
Group I (<2,5 cm) 12 x
II (2,5–4,5 cm) 32
III (4,5–6 cm) 13
IV (>6 cm) 9
PTV tumor (ml) Median 93 <0,001
Range 16–528
Tumor dose (Gy) Median 79,2 <0,001
Range 73,8–90
Lymph node dose (Gy) Median 61 0,38
Range 0–90
ENIa (Gy) Median 45 0,43
Range 0–63
The distribution of patient and tumor characteristics over the four dose groups
was tested with the Kruskal-Wallis-Test (x = not tested, a = elective nodal
irradiation). Significant differences were found – as expected – in group-
related parameters (T-stage, N-stage, tumor dose, PTV tumor)
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esophageal toxicity was scored as chronic.
Esophagus delineation
The external surface of the esophagus was contoured on
each slice from the lowest edge of the cricoid cartilage
to the gastro-esophageal junction. Oral contrast was ad-
ministered before acquisition of the planning CT scan.
DVH parameters
The dose was calculated with collapsed cone (calculation
grid: 3 mm) with correction for tissue inhomogeneity
(Oncentra Masterplan™ 4.1sp2). For multivariate analysis
the following parameters were derived from the dose-
volume histogram for each patient: mean esophageal dose
(MED), Vx (volume receiving at least dose x) in 2.5 Gy
steps from V20 to V70, Dmax, size of the tumor PTV,
doses to the tumor, lymph nodes, and elective lymph
drainage. A recent review of 18 studies found that the
dose range from V20 to V50 including MED was signifi-
cantly related with AE in most studies [23]. We therefore
started our dosimetric analysis at V20. Additionally, the
RTOG working group on quantitative analyses of normal
tissue effects (QUANTEC) describe a clear trend that Vx
with x > 40 Gy correlate with AE [28]. NTCP models were
calculated for all dose levels between 0 and 91 Gy, which
was the highest dose delivered to a single voxel, in 0.1 Gy
steps. The volumes for each step are given as percentages.
Normal tissue complication probability (NTCP)-models
NTCP models assign complication probabilities for organs
at risk to given, generally inhomogeneous dose distri-
butions. In this study the clinical endpoint, for which
the probability of complication was calculated, was AE ≥
grade 2. We compared three models: (1) The Lyman-EUD
model [29–31], which is described by three parameters:
the volume-effect parameter n (sometimes also denoted
as a = 1/n) of the equivalent uniform dose (EUD), a
dose–response steepness parameter m and the dose EUD50
(usually defined as D50) which leads to 50 % probability of
complications. (2) The Lyman-MED model, which is a spe-
cial case of the Lyman-EUD model, with the parameter
n set to 1. (3) The cutoff dose logistic regression model
which correlates the volume VDc receiving a dose Dc or
higher with retrospective toxicity data in terms of a logis-
tic regression (parameters β0 and β1). For the different
NTCP modeling approaches we refer to Söhn et al. [32].
Inter-model comparison was performed with the corrected
Akaike information criterion (AICc). The AICc quantifies the
tradeoff between the model’s quality of fit (likelihood value,
LL) and its complexity (number of model parameters,
k) corrected by the number of cases (i.e. patients) N in
the dataset: AICc = (-2LL + 2 k) + 2*k*(k + 1)/(N-k-1): the
Table 2 Normal tissue complication probability (NTCP) models.
This table shows the parameter estimates for the Lyman-EUD-
model, the Lyman-MED-model and the cutoff-dose logistic
regression model: 95 %-confidence interval, LogLikelihood
(LL), corrected Akaike information criterion (AICc)
Model Parameter estimates 95 % CI LL AICc
Lyman-EUD D50 = 44.9 19.4 75.1 −38.43 83.25
m = 0.34 0.19 1.06
n = 0.34 0.02 19.9
Lyman-MED D50 = 32.8 27.7 52.5 −39.08 82.35
m = 0.48 0.28 1.29
Cutoff-dose Dc = 37.9 28.2 57.3 −38.17 82.67
β0 = -3.06 −5.1 −0.94
β1 = 0.06 0.02 0.12
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model to a given dataset [33].
Biologically equivalent dose
The biologically equivalent dose (EQD2,T) was calculated
with the linear quadratic formalism including a time
factor [34, 35].
Statistical analysis
The distribution of patient, tumor and treatment char-
acteristics in the dose groups was compared with the
non-parametric Kruskal-Wallis-Test. Local and regional
control rates as well as OAS were calculated according
to the Kaplan-Meier-method. Patients without symptoms
(grade 0) or with mild esophagitis (grade 1) were binned
in one group, since pre-existing dysphagia is not always
easy to differentiate from radiation-induced esophagitis
especially in cases with large mediastinal adenopathy.
Considering the time to the maximum degree of AE,
grade 2 or higher esophagitis was chosen as the statistical
endpoint for univariate and multivariate analyses (forward
stepwise regression model) to detect potentially predictive
factors. We used the software packages Mathematica™




23/66 (34.8 %) had no esophagitis (grade 0), 20/66 (30.3 %)
patients developed mild esophagitis (grade 1). With a
median follow up of 686 days (range 84–2921 days), the
actuarial local control rates were 72.6 % and 59.4 % at 2
and 3 years, regional control was 91 %. The median overall
survival was 25 months (range 19.7–30.3 months)
(Additional file 1: Figure S1a-c). No patient was lost
to follow up. The median dose to the primary tumor was
79.2 Gy (78 Gy EQD2,T; range 73,8–90Gy). Involved
lymph nodes were treated with a median dose of 61 Gy
(range 0–90 Gy) and elective lymph drainage with a me-
dian dose of 45 Gy (0–63 Gy). Patient and tumor related
characteristics are summarized in Table 1, treatment re-
lated parameters are shown in Table 2.
Incidences of esophagitis at different toxicity levels
13/66 (19.7 %) cases of esophagitis grade 2 and 10/66 cases
(15.2 %) of esophagitis grade 3 were observed. All patients
could finish their treatment course without interruption.
Onset pattern
Esophageal mucosa is a turn-over tissue, hence AE is a
result of accumulated dose (Additional file 1: Figure S2).
Of those 23 patients who experienced esophagitis ≥ grade
2, 11 (47.8 %) had at least grade 2 esophagitis in week 3
(≥36 Gy), 20/23 patients (87 %) had at least grade 2esophagitis in week 4 (≥54 Gy). In week 5 (≥72 Gy)
the maximum grade of esophagitis was reached in 22/
23 (95.7 %) patients, and in week 6 (≥90) all patients
had reached the maximum esophagitis grade. In 22/23
(95.7 %) patients with clinically relevant AE, all symp-
toms had resumed at the 3-months post-radiotherapy
control. The time course could not be assessed in one
patient with AE grade 3 since he died of pneumonia
nine weeks after the end of radiotherapy.
Chronic toxicity
Two patients experienced chronic esophageal toxicity
grade 3. One patient, who had acute esophagitis grade 1,
received a stent 7 months after treatment. The second
patient, who developed acute esophagitis grade 2, received
a stent 10 months after finishing treatment. For the first
patient, MED and V38 were 31.5 Gy and 45.2 % re-
spectively, for the second MED and V38 were 25.3 Gy
and 34.6 %.
NTCP-models
We performed two Lyman model fits (Lyman-EUD and
Lyman-MED) and a cutoff-dose logistic regression model
fit to the data. With an increase in EUD and MED the
probability of AE rises (Figs. 1 and 2). In the Lyman-EUD
model D50 is 44.9 Gy (95 %-CI: 19.4–75.1), m is 0.34
(95 %-CI: 0.19–1.06), n is 0.34 (95 % CI: 0.02–19.9), in the
Lyman-MED model, D50 is 32.8 Gy (95 % CI: 27.7–
52.5 Gy) and m is 0.48 (95 % CI: 0.28–1.29) (Table 2).
The cutoff dose logistic regression model revealed a
cutoff dose (Dc) of 38 Gy (rounded from 37.9 Gy, see
Table 2) with the highest predictive potential (Fig. 3)
for AE ≥ grade 2. Consistent with the two other NTCP-
models, an increase in V38 leads to a higher probability
of AE (Fig. 4). The Lyman-MED model and cutoff dose
model show the lowest AICc values (82.35 and 82.67
respectively), therefore building a more efficient model fit
to the dataset than the Lyman-EUD model (Table 2).
Fig. 1 NTCP for AE≥ grade 2 is shown as a function of equivalent
uniform dose (EUD). Red x-symbols represent patients with AE ≥
grade 2, green x-symbols represent patients without toxicity. The
actually observed AE rates are shown as bold squares in the centers of
corresponding histogram bins (chosen to represent a comparable
number of patients). Errors shown are binomial confidence intervals, χ2
of the fit and the upper threshold according to Chi-square statistics
(α = 5 %) are given for each model
Fig. 3 Cutoff dose logistic regression model of AE ≥ grade 2:
LogLikelihood (LL) values are plotted against cutoff dose (Dc);
those models with an LL above the horizontal line are statistically
significant (p < 0.05)
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group of patients without or only mild esophagitis, the
median MED was 24.0 Gy (range 3.8–36.6 Gy), the
group of patients who experienced grade 2 reactions had
a median MED of 25.7 Gy (range 16.0–38.4Gy), in grade
3 patients the median MED was 31.2 Gy (24.8–38.4 Gy).
In the respective groups the median V38 was 33.5 %Fig. 2 NTCP for AE ≥ grade 2 is shown as a function of mean esophageal
dose (MED). Red x-symbols represent patients with AE ≥ grade 2,
green x-symbols represent patients without toxicity. The actually
observed AE rates are shown as bold squares in the centers of
corresponding histogram bins (chosen to represent a comparable
number of patients). Errors shown are binomial confidence intervals, χ2
of the fit and the upper threshold according to Chi-square statistics
(α = 5 %) are given for each model(range 0–58.5 %), 37.0 % (range 19.8–57.8 %) and 45.8 %
(range 32.3–67.3 %).
Univariate and multivariate analyses
We hypothesized that the dose given to the esophagus
together with selected clinical parameters might be most
predictive for AE. Therefore, the following variables were
included in the forward stepwise regression (Cox Re-
gression): age, loss of weight, KPS, sex, T, N, tumor
location (peripheral versus central), lymph node dose,
elective dose, V20 to V70 in 2.5 Gy steps, MED, maximum
esophagus dose (Dmax), V38. In the first step (= univariate
analysis), tumor location, N-stage, and the Vx from V30 to
V57.5 and V65 as well as V38 were significant (p < 0.05).
In the second step (= multivariate model) only V38
retained significance (hazard ratio: 1.05; CI 1.01–1.09,
p = 0.007).Fig. 4 Cutoff dose logistic regression model of AE ≥ grade 2: NTCP
based on the cutoff dose model for Dc = 37.9 Gy (this Dc showed the
maximum for LL, see Fig. 3): the probability of AE ≥ grade 2 plotted as
a function of the relative volume receiving ≥ 37.9 Gy
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Although CRT is the standard treatment for locally ad-
vanced NSCLC it is feasible only for 30 % of the patient
population without dose compromises in chemo- and/or
radiotherapy. Especially severe AE would be less well tol-
erated by those patients with poor functional status [1].
On the other hand DART-bid is feasible for unselected
patients [7], including those who would possibly not qual-
ify for full-dose CRT due to co-morbidities. Hence this
sequential accelerated approach is a contribution to the treat-
ment of inoperable NSCLC. Despite an increase to >60 %
with CRT local control still remains moderate for these
patients [4]. It is therefore essential to study the rela-
tion of dosimetric parameters and toxicity in the con-
text of dose escalation for improved local control.
Unlike several clinical series reporting about toxicity
in patients treated with a variety of modalities within the
same treatment series, our patient cohort was exclusively
treated with induction chemotherapy followed by dose
differentiated accelerated radiotherapy (DART-bid). The
median dose was 79.2 Gy (78 Gy EQD2,T, twice daily
fractions of 1.8 Gy), the incidence of AE ≥ grade 2 is
35 %. NTCP assessment by two Lyman models and the
cutoff dose model revealed V38 as the most predictive
dosimetric parameter for AE.
The comparison with literature is generally hampered
by the use of different statistical endpoints, i.e. either AE
grade 2 or 3. With accelerated radiotherapy following in-
duction chemotherapy the reported rate of AE ≥ grade 2
is below 20 %. Patients with smaller tumor burden (lower
V20) received higher doses [36]. This concept contrasts
with the current study, where patients with larger tumors
received higher doses, resulting in a possibly higher rate of
AE. With concomitant radio-chemotherapy the reported
rate of AE is approximately 40 % [10, 16]. A large range of
dosimetric and treatment related parameters is discussed
as potentially predictive [10, 11, 15–22, 37, 38]. In a review
of 18 studies including 2173 patients, six parameters (V20,
V30, V40, V45, V50, MED) were significantly related with
AE in at least two thirds of the studies [23]. The RTOG
working group on quantitative analyses of normal tissue
effects (QUANTEC) uses AE ≥ grade 2 as clinical end-
point, which makes their findings comparable to ours.
The authors conclude that there is a clear trend that Vx
with x > 40 Gy correlate with AE [28].
In the current study we present the Lyman-EUD model
parameters for an accelerated radiotherapy scheme. D50
and the volume parameter n are smaller than in pub-
lished cohorts [15, 39]. In the above mentioned study
by Belderbos, most patients received sequential radio-
chemotherapy in standard fractionation, which is less
intense than our approach. Patients with overall treat-
ment time (OTT) beyond six weeks were treated in an
accelerated mode. The model fit comprises both groupsof patients, which may explain the higher D50 than in
our analysis. Chapet et al. report on patients with sequen-
tial radio-chemotherapy, therefore D50 is even higher [39].
In our patient population, the cutoff-dose model revealed
V38 as the most significant predictor: For example, the
probability of AE ≥ grade 2 was found to be 30 % or less if
V38 was below 34 % (Fig. 4). Since on multivariate analysis,
including a range of patient related parameters, the statisti-
cally most significant factor for AE prediction was V38, we
believe that a specific dose given to the esophagus is more
predictive than patient and tumor related parameters. Of
note, only a small number of individuals received a relevant
percentage of high dose volumes Vx with doses > 60 Gy,
making it difficult to draw any conclusions from our data
in these dose ranges.
It is important to note that the peak around Dc = 38 Gy
is not very sharply defined in Fig. 3, indicating that Vx with
doses in the same range (e.g. V35 to V45) show corre-
lations to toxicity with similar significance. It remains
unclear if this finding has an actual radiobiological
background, or if it is rather an effect of the specific
treatment technique (beam arrangement etc.) which
induces correlations in the DVH dose bins. Statistical
methods like principal component analysis for DVHs
to elucidate such effects have been proposed in literature
[40]. A second – clinically useful – dosimetric parameter,
which is possibly less affected by different beam arrange-
ments, might be MED. The Lyman-MED model also
describes the dataset efficiently. Thus, based on the
findings for our patient cohort, if we accept – again – a
30 %-probability of AE ≥ grade 2, the MED should not
exceed 24 Gy in patients treated with DART-bid (Fig. 2).
Huang et al. also propose an MED model based on
AE ≥ grade 2 to estimate NTCP [37]. Judging from the
logistic regression graph in their paper, in order to achieve
a 30 %-probability of AE ≥ grade 2, MED should be <
27 Gy in patients treated with radiotherapy only or se-
quential radio-chemotherapy. This is slightly higher than
in our model and possibly due to the fact that the current
study included only patients who received accelerated
radiotherapy.
Because esophageal mucosa is a turn-over tissue, AE
depends on accumulated total dose. In the study by
Wei, which included patients with concomitant radio-
chemotherapy only, AE ≥ grade 2 started during the
second week of radiotherapy with increasing incidences
towards the end of the treatment series [21]. This onset
pattern is comparable to DART-bid.
Still, one has to bear in mind that current models do
not account for the velocity of dose accumulation in ac-
celerated schedules. On top of that, our model fit as well
as those presented in other studies are descriptive of the
current dataset, and an extrapolation to another irradi-
ation technique, e.g. IMRT, has to be taken with caution.
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and can be blurred by esophageal infection, pre-existing
gastro-esophageal reflux and/or dysphagia [28], which is
a major limitation for a comparison between studies. Fi-
nally, the delineation of the esophagus on the planning
CT scan is crucial: Chapet excluded the cervical esopha-
gus in his analysis [39], whereas in the current analysis –
like Belderbos [15] – we delineated the esophagus to the
lower limit of the cricoid cartilage. Additionally, the daily
dose exposure of the esophagus may vary due to inter-
and intrafraction organ mobility [41].Conclusion
The rate of AE ≥ grade 2 in DART-bid is slightly lower
than in standard concomitant radio-chemotherapy sched-
ules, despite higher total doses and hence, higher loco-
regional tumor control rates. The most significant predictor
of AE was found to be V38 (volume of the esophagus that
receives at least 38 Gy, 95 %-CI 28.2–57.3). Although the
results of the current study need to be validated in inde-
pendent cohorts treated similarly, our findings allow us to
assume that the probability of AE ≥ grade 2 is 30 % or less
if V38 does not exceed 34 %. A second clinically useful
parameter in treatment planning may be MED (mean
esophageal dose).Additional file
Additional file 1: Figure S1. Clinical outcome. With a median follow
up of 686 days, the actuarial LC rates for all patients (n = 66) are 73 %
and 59 % at 2 and 3 years, regional control is 91 %, median OAS in
25 months. Figure S2 Onset pattern and time course of acute esophagitis
(AE)≥ grade 2. Cumulative incidence of AE (66 patients = 100 %): < grade 2
(blue), grade 2 (red) and grade 3 (green). AE≥ grade 2 starts in week 3 (11
patients), increases towards the last week of treatment (23 cases of AE ≥
grade 2) and resumes completely in 22 patients within 12 weeks after the
end of radiotherapy (exact numbers in the table below the graph, * 1
patient died for pneumonia 9 weeks after completion of radiotherapy).
Table S1 Univariate and multivariate analyses of dosimetric and clinically
relevant parameters (*Cox Regression, forward stepwise): KPS Karnofsky
Performance Score, MED mean esophageal dose, Dmax maximum dose to
the esophagus; significant p-values (<0.05) in bold letters. On multivariate
analysis only V38 retained significance (HR: 1.05; CI 1.01–1.09, p = 0.007).Abbreviations
AE: Acute esophagitis; DART-bid: Dose differentiated accelerated
radiotherapy; NTCP: Normal tissue toxicity complication probability;
MED: Mean esophageal dose; Dc: Cutoff dose; NSCLC: Non-small cell lung
cancer; CRT: Concomitant radiochemotherapy; OAS: Overall survival;
CHART: Continuous hyperfractionated accelerated radiotherapy; LC: Local
control; Vx: Volume receiving a certain dose; Dmax: Maximum dose to any
point of an organ; KPS: Karnofsky Performance Score; EUD: Equivalent
uniform dose; n: Volume-effect parameter in the Lyman-EUD-model;
m: Dose–response steepness parameter in the Lyman-EUD-model; EUD50
(= D50): Dose that leads to 50 % probability of complications; AICc: Corrected
Akaike information criterion; EQD2,T: Time factor corrected biologically
equivalent dose; CI: Confidence interval; QUANTEC: Quantitative analyses of
normal tissue effects; OTT: Overall treatment time; DVH: Dose volume
histogram; IMRT: Intensity modulated radiotherapy.Competing interests
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